Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia Intermedia

Trial Profile

A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia Intermedia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 17 Jun 2021 Results analyzing MCV variation as an early predictor of response to Luspatercept by using data from phase II/III clinical trials (NCT01749540, NCT02268409, NCT02604433, NCT03342404, NCT04064060) presented at the 26th Congress of the European Haematology Association
    • 12 Jul 2020 Data from patients with beta-thalassemia in 3 studies (NCT01749540, NCT02268409, NCT02604433) assessing population pharmacokinetics and exposure-response relationship of luspatercept in patients with beta-thalassemia under a titration-to-response dosing regimen published in the Journal of Clinical Pharmacology
    • 10 Jan 2019 According to an Acceleron Pharma media release, the journal Blood has published results from this trial. Antonio Piga was a lead author of the newly published study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top